Table 2. Association of factors with time to loss from DR-TB treatment—2009–2013 (n = 373*).
| Variable | Univariate analysis | Multivariate analysis | Multivariate analysis^ | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| Age | ||||||
| 0–15 years | 0.94 (0.45–1.95) | 0.12 | 1.02 (0.49–2.11) | 0.97 | 1.07 (0.25–4.57) | 0.93 |
| >15–25 years | 2.20 (1.38–3.50) # | 0.001 # | 2.43 (1.52–3.88) # | 0.001 # | 2.48 (1.37–4.47) | 0.003 # |
| >25–35 years | 1.40 (0.92–2.14) | 0.87 | 1.57 (1.02–2.42) # | 0.04 # | 1.66 (0.97–2.86 | 0.07 |
| >35 years | Ref | |||||
| Gender: Male | 1.79 (1.26–2.53) # | 0.001 # | 1.93 (1.35–2.75) # | <0.001 # | 2.08 (1.31–3.28) | 0.002 # |
| HIV positive | 0.98 (0.56–1.15) | 0.24 | ||||
| Resistance pattern | ||||||
| Rifampicin mono resistance | ref | |||||
| MDR no 2ndline resistance | 0.96 (0.64–1.45 | 0.85 | ||||
| MDR plus 2ndline resistance | 0.71 (0.34–1.50) | 0.37 | ||||
| MDR 2ndline resistance unknown | 0.71 (0.33–1.54) | 0.38 | ||||
| Presumed DR-TB | 0.59 (0.25–1.42) | 0.24 | ||||
| Treatment initiation site | ||||||
| PHC Clinic | ref | |||||
| Hospital | 0.69 (0.39–1.22) | 0.21 | ||||
| Sub-acute facility | 0.86 (0.49–1.50) | 0.60 | ||||
| Counselling sessions completed | 0.83 (0.55–1.26) | 0.94 | ||||
| Culture conversion at 4 months | 2.07 (0.90–4.77) | 0.09 | 2.14 (0.93–4.94) | 0.07 | ||
* 79 patients who died while on treatment were excluded from this analysis
#statistically significant
^ Sensitivity analysis-Multivariate analysis including Culture conversion status at 4 months of treatment